Interpace Biosciences
New Jersey, United States · Biotechnology, Genetics, Healthcare · 107 employees
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Funding history
- Funding Round — $47.0M — Oct 2024
- Funding Round — $47.0M — Jan 2020
- Funding Round — $14.0M — Jul 2019
- Series pre-seed — $111K — Jan 2017
Recent signals
- Dec 03, 2025: SEC 8-K (1.02): On December 3, 2025, Interpace Biosciences, Inc. announced the full repayment of its outstanding term loan facility with BroadOak Capital Partners, effectively terminating the agreement before its scheduled maturity date. This repayment signifies a strategic move to reduce debt obligations, thereby improving the company's financial flexibility. The transaction involves a significant financial commitment, although the exact amount of the loan facility is not disclosed in this filing. The early termination of this agreement may positively impact the company's cash flow and operational strategies moving forward.
- Oct 16, 2024: Raised $47.0M
- Oct 15, 2024: Interpace Biosciences Announces Capital Restructuring with Investors for Uplisting to Nasdaq
- Jan 27, 2020: Raised $47.0M
- Jul 29, 2019: Raised $14.0M
- Jan 27, 2017: Raised $111K in Series pre-seed
See plans & pricing → Track Interpace Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.